Prognostic impact of tumor microenvironment in diffuse large B-cell lymphoma uniformly treated with R-CHOP chemotherapy

American Journal of Clinical Pathology

Volumn 145, Issue 4, 2016, Pages 514-523

  Gomez Gelvez, Juan C ^a,b   Salama, Mohamed E ^c   Perkins, Sherrie L ^c   Leavitt, Matthew ^d   Inamdar, Kedar V ^a  

^a HENRY FORD HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^d Section of Electrophysiology   (United States)

Author keywords

Diffuse large B cell lymphoma; Macrophages; Microvasculature; Prognostic impact; Regulatory T lymphocytes; Tumor microenvironment

Indexed keywords

CD34 ANTIGEN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CAPILLARY DENSITY; EVENT FREE SURVIVAL; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LOW RISK POPULATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; TISSUE MICROARRAY; TUMOR MICROENVIRONMENT; VERY ELDERLY; AREA UNDER THE CURVE; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BIOMARKERS, TUMOR; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MICROENVIRONMENT; VINCRISTINE; YOUNG ADULT;

EID: 84981263300     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1093/AJCP/AQW034     Document Type: Article

References (41)

1. Stein H, Warnke RA, Chan WC, et al. Diffuse large B-cell lymphoma, not otherwise specified. In: SH Swerdlow, E Campo, NL Harris, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:233-237.
2. Alexander DD, Mink PJ, Adami HO, et al. The non- Hodgkin lymphomas: A review of the epidemiologic literature. Int J Cancer. 2007;120:1-39.
3. Fisher RI, Shah P. Current trends in large cell lymphoma. Leukemia. 2003;17:1948-1960.
4. Coiffier B, Thieblemont C, Van Den Neste E, et al. Longterm outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040-2045.
5. Coiffier B. Rituximab and CHOP-like chemotherapy in good-prognosis diffuse large-B-cell lymphoma. Nat Clin Pract Oncol. 2006;3:594-595.
6. Coiffier B. Treatment of non-Hodgkin's lymphoma: A look over the past decade. Clin Lymphoma Myeloma. 2006;7:S7-S13.
7. Nastoupil LJ, Rose AC, Flowers CR. Diffuse large B-cell lymphoma: Current treatment approaches. Oncology. 2012;26:488-495.
8. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027-5033.
9. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26:4587-4594.
10. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non- Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
11. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857-1861.
12. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20' B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373-2380.
13. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
14. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
15. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313-2323.
16. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282.
17. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29:200-207.
18. Mittal S, Marshall NA, Duncan L, et al. Local and systemic induction of CD4-CD25- regulatory T-cell population by non-Hodgkin lymphoma. Blood. 2008;111:5359-5370.
19. Wang J, Ke XY. The four types of Tregs in malignant lymphomas. J Hematol Oncol. 2011;4:50.
20. Coupland SE. The challenge of the microenvironment in B-cell lymphomas. Histopathology. 2011;58:69-80.
21. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108:804-811.
22. Beyer M, Schultze JL. Regulatory T cells: Major players in the tumor microenvironment. Curr Pharm Des. 2009;15:1879-1892.
23. Yang ZZ, Novak AJ, Stenson MJ, et al. Intratumoral CD4-CD25- regulatory T-cell-mediated suppression of infiltrating CD4- T cells in B-cell non-Hodgkin lymphoma. Blood. 2006;107:3639-3646.
24. Piccirillo CA, Shevach EM. Cutting edge: Control of CD8' T cell activation by CD4'CD25' immunoregulatory cells. J Immunol. 2001;167:1137-1140.
25. Wei WZ, Morris GP, Kong YC. Anti-tumor immunity and autoimmunity: A balancing act of regulatory T cells. Cancer Immunol Immunother. 2004;53:73-78.
26. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061.
27. Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22:329-341.
28. Roncador G, Brown PJ, Maestre L, et al. Analysis of FOXP3 protein expression in human CD4-CD25- regulatory T cells at the single-cell level. Eur J Immunol. 2005;35:1681-1691.
29. Perry AM, Cardesa-Salzmann TM, Meyer PN, et al. A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2012;120:2290-2296.
30. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957-2964.
31. Lee NR, Song EK, Jang KY, et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma. 2008;49:247-256.
32. Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3- regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008;93:193-200.
33. Zu Y, Steinberg SM, Campo E, et al. Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphomas. Leuk Lymphoma. 2005;46:693-701.
34. Hedvat CV, Hegde A, Chaganti RS, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol. 2002;33:968-974.
35. Nam SJ, Go H, Paik JH, et al. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma. 2014;55:2466-2476.
36. Riihijarvi S, Fiskvik I, Taskinen M, et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: A correlative study from a Nordic phase II trial. Haematologica 2015;100:238-245.
37. Pulford KA, Rigney EM, Micklem KJ, et al. KP1: A new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections. J Clin Pathol. 1989;42:414-421.
38. Cardesa-Salzmann TM, Colomo L, Gutierrez G, et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica. 2011;96: 996-1001.
39. Marinaccio C, Ingravallo G, Gaudio F, et al. Microvascular density, CD68 and tryptase expression in human diffuse large B-cell lymphoma. Leuk Res. 2014;38:1374-1377.
40. Horna P, Cuenca A, Cheng F, et al. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood. 2006;107:2871-2878.
41. Plumas J, Jacob MC, Chaperot L, et al. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood. 1998;91:2875-2885.